Table 2 Prior vaccination and documented SARS-CoV-2 infection among cases with BA.2 and BA.4/BA.5 lineage SARS-CoV-2 infection

From: Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome

Characteristic

 

n (%)

OR (95% CI)

  

BA.2 (No SGTF)

BA.4/BA.5 (SGTF)

Unadjustedc

Adjustedc

  

N = 46,976

N = 59,556

  

Vaccination—doses receiveda

 

0 doses

7543 (16.1)

9422 (15.8)

ref.

ref.

 

1 dose

1121 (2.4)

1503 (2.5)

1.08 (0.97, 1.21)

1.09 (0.98, 1.23)

 

2 doses

11,743 (25.0)

14,038 (23.6)

1.02 (0.97, 1.07)

1.04 (0.98, 1.10)

 

3 doses

23,477 (50.0)

28,902 (48.5)

1.08 (1.03, 1.13)

1.15 (1.09, 1.21)

 

≥4 doses

3092 (6.6)

5691 (9.6)

1.14 (1.06, 1.22)

1.38 (1.27, 1.49)

Prior infection (≥90 days before positive test)b

 

None documented

45,518 (96.9)

56,417 (94.7)

ref.

ref.

 

Any documented

1458 (3.1)

3139 (5.3)

1.52 (1.40, 1.65)

1.55 (1.43, 1.69)

  1. SGTF S gene target failure, here interpreted as a proxy for SARS-CoV-2 lineage, CI Confidence interval, OR Odds ratio.
  2. aVaccine doses received are summed across all products.
  3. bWe present estimates stratified by both vaccination and prior documented infection (hybrid immunity) in Table S4. We present analyses subset to cases with documented prior infection, and exploring bias resulting from potential misclassification of prior infection status, in Table S8 and Fig. S1.
  4. cOdds ratios and adjusted odds ratios are estimated using logistic regression models defining cases’ calendar week (or weekend) of diagnosis as strata. Adjusted estimates control for all variables listed in Table 1 as covariates with the exception of nirmatrelvir-ritonavir receipt.
Back to article page